Idea
AI agent platform that maps drug competitive landscapes to accelerate biotech due diligence for venture analysts and investors
Research Paper
Core Innovation
This paper introduces an LLM-based AI agent that integrates fragmented, paywalled, and multimodal data to identify drug competitors accurately. It also presents a novel evaluation benchmark from private VC diligence memos and a validating agent to reduce false positives. This approach significantly improves recall and reduces analyst turnaround time compared to prior manual or less integrated methods.
Market Size (TAM)
$2–10B TAM, $1–2B SAM; assumption: biotech and pharma due diligence market growing with AI adoption in drug development analysis.
Potential Customers & Pain Points
- Biotech Venture Capital Firms Needing Faster Due Diligence
- Pharmaceutical Companies Conducting Competitive Analysis
- Drug Development Analysts Facing Fragmented Data Sources
Business Model
Subscription-based SaaS platform with tiered pricing for VC firms and pharma companies; potential API access for integration.
Competitive Landscape
- Informa Pharma Intelligence
- Clarivate
- GlobalData
Implementation Challenges
- Access to paywalled and proprietary data
- Ensuring data privacy and compliance
- Integration with existing analyst workflows
Validation Strategy
- Pilot deployment with select biotech VC firms
- Measure recall and turnaround time improvements
- Iterate based on user feedback and data coverage
Research Paper Overview
LLM-Based Agents for Competitive Landscape Mapping in Drug Asset Due Diligence
Summary
This paper presents a competitor-discovery AI agent that maps the competitive landscape of drug indications by retrieving and normalizing drug attributes from fragmented, paywalled, and multimodal data sources. It introduces a novel LLM-based evaluation benchmark derived from private biotech VC diligence memos and a validating agent to filter false positives, achieving 83% recall and reducing analyst turnaround time by ~20x in production.